OTC Switch Offers Firms Opportunities To Diversify Earnings – Morgan Stanley
This article was originally published in The Tan Sheet
Rx-to-OTC switches offer drug firms a "meaningful opportunity" to diversify their earnings, which is gaining importance in an "increasingly challenging pharmaceutical landscape" Morgan Stanley market analysts say
You may also be interested in...
Incoming Novartis CEO Joe Jimenez plans to expand the Swiss firm's consumer health division over the next few years after he takes the reins from his predecessor Daniel Vasella
Merck's Schering-Plough Consumer HealthCare Products division will launchZegerid OTC in the first half of 2010 as the first dual-ingredient OTC proton pump inhibitor
A federal court decision allows Teva Pharmaceutical Industries to continue marketing the generic Rx proton pump inhibitor pantoprazole. The U.S. Court of Appeals for the Federal Circuit affirmed the denial of a motion for a preliminary injunction filed by Wyeth and Altana against the generic equivalent to Wyeth's Protonix delayed-release tablets, the Jerusalem-based firm said May 14. Pantoprazole has received a positive opinion in the European Union for a switch to nonprescription status, and has been mentioned for possible OTC switch in the U.S. (1"The Tan Sheet" Feb. 4, 2008, p. 3). Teva launched generic pantoprazole in December 2007 and said it is still involved in patent litigation with Wyeth and Altana over the product